Selank vs Semax: Comparing the Russian Nootropic Peptides

Selank and Semax are both Russian-origin synthetic neuropeptides with regulatory approval in Russia, overlapping nootropic and anxiolytic applications, but fundamentally distinct mechanisms.

Semax: BDNF Upregulation via Melanocortin Receptors

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of ACTH(4-10). It does not activate ACTH receptors (MC2R) but instead acts through MC4R and MC5R in the brain, primarily upregulating BDNF and its receptor TrkB in the hippocampus and cortex.

Dolotov OV et al. (*BMC Neuroscience*, 2006): intranasal Semax at 50 mcg in rats produced a 1.8-fold increase in hippocampal BDNF mRNA within 1 hour, sustained for 24 hours.

Clinical evidence: Gusev EI et al. (*Cerebrovascular Diseases*, 1997) — randomised trial in acute ischaemic stroke, intranasal Semax at 18 mcg/day for 5 days → significantly improved neurological recovery scores at 30 days vs placebo, attributed to neuroprotection of penumbral neurons via BDNF.

Semax received Russian regulatory approval (Ros-8803) in 1996 for ischaemic stroke, optic nerve atrophy, and cognitive impairment.

Selank: Anxiolysis via GABA-A Modulation

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analogue of tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro extension for metabolic stability. Its primary mechanism is modulation of the GABA-A receptor complex, producing anxiolytic effects comparable to benzodiazepines without sedation, dependence potential, or cognitive impairment.

Zozulya AA et al. (*Zhurnal Nevrologii i Psikhiatrii*, 2014) — double-blind RCT comparing Selank to medazepam (benzodiazepine) in 62 patients with generalised anxiety disorder:

• Both produced significant HAM-A score reductions at 4 weeks
• Selank showed comparable anxiolytic efficacy with superior cognitive performance on neuropsychological testing
• No withdrawal syndrome on Selank discontinuation

Selank received Russian regulatory approval in 2009 for generalised anxiety disorder.

Direct Comparison

Both are approved pharmaceutical drugs in Russia but classified as research compounds in the US, EU, and most Western jurisdictions.

<!-- deep-links-v1 -->

Broader Nootropic Peptide Research Landscape

Selank and Semax are the most studied synthetic nootropic peptides, but the cognitive peptide research space is substantially broader. N-Acetyl Selank and N-Acetyl Semax are acetylated analogues with improved intranasal bioavailability and extended receptor residence time compared to the native forms. Dihexa, an angiotensin IV analogue, promotes HGF-mediated synaptogenesis and is reported to be orders of magnitude more potent than BDNF in promoting long-term potentiation in rodents. P21 enhances hippocampal neurogenesis via CXCR4 pathway activation in aged rodent models. Cerebrolysin, a neuropeptide mixture with clinical evidence in Alzheimer's disease, provides the benchmarked clinical reference in the nootropic peptide space. PACAP-38 activates adenylate cyclase-coupled receptors to stimulate neurotrophin production and neuroprotection. PE-22-28 is a spirolactam TREK-1 inhibitor with rapid antidepressant and pro-cognitive effects in preclinical models.

Neurochemical and Regulatory Peptides

Orexin-A and Orexin-B regulate wakefulness, attention, and executive function through hypocretin receptor signaling — deficiency is the established mechanism of narcolepsy. Vasopressin (AVP) has well-documented effects on memory consolidation through V1b receptors in the hippocampus and amygdala. DSIP (Delta Sleep-Inducing Peptide) modulates sleep architecture and stress-induced delta activity, with anti-oxidative properties in aging brain models. Beta-Endorphin, the endogenous opioid produced from POMC, affects mood, motivation, and cognitive flexibility through mu-opioid receptors. TRH (Thyrotropin-Releasing Hormone) has cognitive-enhancing and analeptic properties independent of its thyroid-stimulating function. Neurotensin modulates dopaminergic signaling and is studied for schizophrenia and substance use disorder models. Galanin regulates hippocampal cholinergic transmission and is implicated in Alzheimer's disease pathology. Nociceptin/Orphanin FQ is the endogenous NOP receptor ligand with complex roles in anxiety, memory, and pain modulation. FGL Peptide, derived from neural cell adhesion molecule (NCAM), activates FGFR1 to promote synaptic maintenance and neuroprotection. Crystagen, Cerluten, and Pinealon are tissue-targeted brain bioregulators from the Khavinson library with preclinical evidence for region-specific cognitive protection.